Each year there are approximately 750,000 deaths and more than one million newly diagnosed cases of cancer in the European Community (Moller-Jensen et al., 1990) . Although progress has been made in recent years in the development of effective cancer therapies, at least for some tumour types, this progress has not always translated into changes in clinical practice. This is not only a European problem as a report of the USA Government Accounting Office (1988) indicated that many patients are not receiving state-of-the-art therapy, in particular 37% of premenopausal women with stage II, node positive breast cancer did not receive adjuvant therapy although it is known to bring benefit.
There are several important reasons for this. One is that the results are often communicated through articles in a diverse assortment of scientific journals, with consequent publication delays and more importantly perhaps a restricted readership. A second reason is that the evidence so published is not sufficiently compelling to convince clinicians of the value of the new therapy compared to the standard therapy with which they are familiar. It may be that the result requires confirmation in a large collaborative trial before this uncertainty is removed. A third reason, associated with the second, is that the effect of the new therapy, although established beyond reasonable doubt, may not appear very striking to the clinician in the context of an individual patient about to be treated. Thus a proved 5% advantage of a new therapy does not offer a great deal to an individual patient. Although the public health impact of a small but important difference may be considerable and may save many lives per year, it may not be appreciated by the attending physician or an individual patient.
Modern computer technology can be exploited to assist both in the rapid dissemination of results and in the organisation of large collaborative trials run on a regional, national or international basis. The need for, and appropriate size of, such trials has been reviewed by Freedman (1989 These databases provide clinical oncologists with an overview of the activity of the major cancer cooperative groups. They also constitute a first attempt at an international registry of on-going clinical trials: the relevance of such a registry when evaluating the worth of alternative investigational therapies has been recognised for several years (Dickersin, 1992; Simes, 1986) . It is expected that the number of on-line databases will increase to include all clinical trials in cancer, whether on-going or closed, from national and regional groups, and from individual institutions.
The main advantage of these computerised databases over the traditional sources of information, such as journals or periodicals, is that they can be regularly updated and allow quick and easy access to the latest information. Information can be selectively retrieved, with only those details which are relevant being displayed or printed.
On-line randomisation
One of the attractive and original features of EuroCODE is the on-line registration and randomisation system it provides for entry of patients into clinical trials. The responsible clinician merely logs into EuroCODE at any time, day or night, 7 days a week, and the system checks with the clinician the patient eligibility for a given protocol. This is done by asking the investigator a series of questions from the trial protocol relating to the patient. If all answers are satisfactory the patient is accepted into the system and, in the case of randomised trials, the appropriate treatment is assigned. The patient data including allocated treatment is automatically added to the study data file and a confirmation sheet is automatically printed in the clinicians office. Patient entry through EuroCODE provides the responsible Trials Office with up to the minute knowledge of patient entry and initiates the other activities associated with patient entry to the particular protocol, for example, warns the reference pathologist to expect a specimen.
There are numerous advantages to an on-line registration system over the more usual telephone call. For example, spelling mistakes and language difficulties which are commonly encountered with telephone registration are greatly reduced. The system allows a tighter control of eligibility criteria and prognostic information. These features are particularly helpful in phase II trials where a lot of 'on-study' information must be requested and checked before the patient is entered on the trial. The principal advantage for phase III trials is the 24 hour service so that patients can be randomised at any time and without telephoning a Data Centre. In this way, EuroCODE encourages wide and international participation in cancer clinical trials. This is particularly useful as large-scaIe collaborative and international trials, such as the AXIS trial in colorectal cancer recently launched by the UKCCCR, become more common. A joint MRC/EORTC Phase III trial of Cisplatin, Methotrexate and Vinblastine (CMV) in advanced bladder cancer anticipates randomisations through EuroCODE from as far afield as Canada, Finland and Norway.
Exchange of data between trial offices There is currently increasing awareness of the need for collaborative efforts between the different Trial Offices, both for very large trials seeking to detect small treatment improvements in common cancers and for more rapid accrual to medium sized trials in rarer tumours. One of the benefits of EuroCODE has been that the national trial organisations can be in closer contact with each other, with exchange of data between the offices taking place across EuroCODE. It also facilitates cooperation between EORTC and national organisations supervising national cancer clinical trials. This may not be of obvious consequence to the clinician as a user, but is an example of the way in which the EuroCODE project has improved communications at all levels.
Electronic mail An additional benefit of the EuroCODE network is that oncologists can exchange electronic mail (Email) with other investigators and with the Trial Offices that coordinate collaborative trials. This inexpensive method of communication can help reduce the administrative burdens of both the Trial office and the clinicians. It may also guarantee that important news about ongoing protocols, for example unexpected toxicities or treatment adjustments, get communicated to all investigators simultaneously and accurately.
Thus Email is used for patient data exchange between the 
Future developments
Future developments will allow Cancer Trial Offices to exchange data through the network with appropriate considerations of security. It is anticipated that investigators will also be able to enter all their patient data directly on-line if they choose. This will void the need for patient data forms to be sent through the post. In order to maintain security, the investigator will not have access to the trial data once entered. The Trial Office will still oversee the data quality by appropriate checking facilities as described, for example, by the COMPACT Steering Committee (1990) . This development of on-line entry could considerably improve the quality, completeness and timeliness of the computer file of trial data. This is particularly useful and important for any interim analysis to be presented to a Data Monitoring Committee which oversees the trial results as they are emerging.
The above development will have several longer term implications. It will be possible to provide translation of the data sheets into other languages, in order to facilitate on-line data entry to multinational trials. Email facilities, possibly augmented by computer driven FAX cards, will be able to provide a convenient method for sending automatic requests for missing or overdue data to hospitals.
The updated list of cancer protocols maintained by the UKCCCR is in the process of being made available as an on-line document accessed through EuroCODE. The British Association of Cancer United Patients (BACUP) is one group which has already expressed interest in linking to EuroCODE in order to access the register. In this way they would keep abreast of the current developments in cancer patient management and care and be able to respond to patients' requirements for information on clinical trials in cancer. This would clearly be an important development in terms of encouraging patient entry.
